Capricor Therapeutics (NASDAQ:CAPR) reported a notable insider transaction on March 31, 2026, when Chief Financial Officer Anthony Bergmann sold 25,000 shares of the company’s common stock for approximately $753,152. The disposition was carried out at weighted average prices ranging from $30.00 to $30.32 per share.
The sale was implemented automatically under a pre-established 10b5-1 trading arrangement that Bergmann adopted in December 2025. On the same calendar day, Bergmann exercised stock options to obtain an additional 25,000 shares of Capricor common stock at an exercise price of $3.18 per share, costing $79,500 in aggregate.
Those options are part of a stock option plan in which the awards vested on a monthly basis beginning February 1, 2022. The options have an expiration date of January 3, 2032.
Market context for the transactions is mixed. Capricor’s shares have climbed 209% over the past 12 months and were trading at $30.06 at the time of the report, giving the company a market capitalization of $1.73 billion. Yet multiple analysts continue to place higher valuations on the stock: InvestingPro notes price targets in the $43 to $63 range and highlights additional commentary through 11 ProTips for CAPR subscribers. Separately, Cantor Fitzgerald has maintained an Overweight rating and set a $62.00 price target.
Recent financial results provide part of the backdrop for investor attention. Capricor posted fourth-quarter fiscal 2025 earnings that showed an EPS of -0.62, missing the forecasted -0.51 and producing a negative surprise of 21.57%. Alongside the earnings release, the company reiterated clinical and regulatory developments that market participants will track closely.
Among those developments is a scheduled PDUFA date on August 22, 2026, for deramiocel, Capricor’s cardiosphere-derived cell therapy candidate for Duchenne muscular dystrophy. The company also disclosed new HOPE-3 data presented at a Muscular Dystrophy Association event, signaling ongoing clinical activity in the program.
For investors and analysts, the combination of insider activity, analyst valuations and advancing clinical milestones frames an array of near-term items to monitor. The sale planned through a 10b5-1 arrangement and the concurrent exercise of long-held options are documented corporate actions; the company’s financial results and regulatory timeline provide the substantive catalysts likely to influence market perception going forward.